Bottom line
XBI vs BIPIX: the short answer
XBI (State Street(R) SPDR(R) S&P(R) Biotech ETF) and BIPIX (Biotechnology Ultrasector Profund) are quite different portfolios: only about 28% of their top holdings (by weight) are shared.
XBI is cheaper at 0.35% vs 1.52% — a difference of $117 a year per $10,000 invested.
Over five years, BIPIX returned +6.1% a year vs −2.7% for XBI (reporting dates differ).
Updated Nov 19, 2026
XBI vs BIPIX side by side
| XBI | BIPIX | |
|---|---|---|
| Type | ETF | Mutual fund |
| Fund family | SPDR (State Street) | ProShares |
| Category | Technology Sector | Technology Sector |
| Expense ratio | 0.35% | 1.52% |
| Annual cost per $10k | $35 | $152 |
| 10-yr cost on $10k (prospectus) | $443 | $1,813 |
| Max front load | None | — |
| 12b-1 fee | 0% | 0% |
| 1-yr return | +35.8% | −5.2% |
| 5-yr return (annualized) | −2.7% | +6.1% |
| 10-yr return (annualized) | +5.8% | +4.4% |
| Best quarter | +44.4% | +35.4% |
| Worst quarter | −26.2% | −24.1% |
| Net assets (fund) | $10.7B | $118.7M |
| Number of holdings | 161 | 159 |
| Portfolio turnover | 71% | 52% |
| Returns as of | Dec 31, 2025 | Dec 31, 2024 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | XBI | BIPIX | Difference |
|---|---|---|---|
| 2024 | +1.1% | −5.2% | +6.3% |
| 2023 | +7.5% | +10.1% | −2.6% |
| 2022 | −25.8% | −13.4% | −12.3% |
| 2021 | −20.5% | +23.8% | −44.3% |
| 2020 | +48.2% | +20.1% | +28.1% |
| 2019 | +32.2% | +23.6% | +8.6% |
| 2018 | −14.9% | −12.2% | −2.7% |
| 2017 | +43.7% | +34.7% | +9.0% |
| 2016 | −15.4% | −23.8% | +8.3% |
| 2015 | +13.6% | +3.1% | +10.5% |
Source: Fund prospectus bar charts
Holdings overlap
12 of XBI's top 25 holdings also appear in BIPIX's top 25.
| Holding | XBI | BIPIX |
|---|---|---|
| Apogee Therapeutics Inc | 1.49% | 1.29% |
| Twist Bioscience Corp | 1.41% | 1.08% |
| Oruka Therapeutics Inc | 1.38% | 1.20% |
| Kymera Therapeutics Inc | 1.36% | 1.05% |
| Praxis Precision Medicines Inc | 1.29% | 1.02% |
| Erasca Inc | 1.27% | 1.08% |
| Revolution Medicines Inc | 1.20% | 1.04% |
| CG oncology Inc | 1.20% | 1.03% |
| Dianthus Therapeutics Inc | 1.18% | 1.12% |
| Natera Inc | 1.16% | 0.99% |
| Cogent Biosciences Inc | 1.14% | 0.99% |
| Travere Therapeutics Inc | 1.13% | 0.95% |
Source: SEC Form N-PORT
XBI top 10
- State Street Global Advisors — 5.87%
- Apogee Therapeutics Inc — 1.49%
- Moderna Inc — 1.41%
- Twist Bioscience Corp — 1.41%
- Oruka Therapeutics Inc — 1.38%
- Kymera Therapeutics Inc — 1.36%
- Viking Therapeutics Inc — 1.30%
- Praxis Precision Medicines Inc — 1.29%
- Erasca Inc — 1.27%
- Revolution Medicines Inc — 1.20%
BIPIX top 10
- N/a — 6.70%
- N/a — 5.15%
- N/a — 4.12%
- N/a — 4.12%
- N/a — 3.16%
- Agpxx — 2.40%
- Apogee Therapeutics Inc — 1.29%
- N/a — 1.24%
- Oruka Therapeutics Inc — 1.20%
- Dianthus Therapeutics Inc — 1.12%
FAQ
What is the difference between XBI and BIPIX?
Which is cheaper, XBI or BIPIX?
Should I own both XBI and BIPIX?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.